Tobacco Treatment TrAining Network in Greece & Cyprus

NCT03040349 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 300

Last updated 2017-02-02

No results posted yet for this study

Summary

The overall aim of the TiTAN Greece \& Cyprus project is to expand the Global Bridges Tobacco Treatment Training Network in the WHO Europe region through a focus on primary health care providers in Greece and Cyprus. A robust evaluation will be conducted alongside the TiTAN program. A pre-post evaluation will be used to examine the impact on the TiTAN program on:

1. Provider engagement (number of providers attending training), number of local champions;
2. Provider knowledge, beliefs, perceived behavioral control, and intentions related to the delivery of tobacco treatment;
3. Rates of evidence-based tobacco treatments (5As) are delivered to patients who smoke;
4. Provider satisfaction with training program, resources, and network outreach activity and areas for improvement; and
5. Estimates on the impact on patient-level outcomes including number of patient quit smoking at 1 and 3-month follow-up.

All PHC providers will be surveyed before and after the intervention program is delivered. We will randomly select a sub-sample of providers and will survey patients from their practice before and after the intervention program in order to validate changes in 5As delivery. Qualitative interviews will be completed with a sub-sample of providers at the end of year 1.

Conditions

  • Tobacco Use

Interventions

BEHAVIORAL

Training

The training program consists of a one-day core session addressing tobacco use with patients in the context of a busy primary care practice setting.The curriculum design was designed to be 2/3 theory and 1/3 practical. The program employs teaching techniques including role-play and case-study approaches known to enhance practice change.

BEHAVIORAL

Provider and Patient Tools

Provider and patient tools were translated and adapted for use in primary care settings in Greece. A tool kit of resources will be distributed to providers which includes: patient tobacco use survey; provider consult form; provider medication reference sheet; patient quit plan booklet; and, waiting room posters. The provider consult form uses a checklist style set-up and provides real-time reminders for conducting an initial smoking cessation visit and follow-up appointments. The TiTAN Crete tools are available online at www.titan.uoc.gr

BEHAVIORAL

E-blast and Webinars

In order to develop the network and continue to provide training opportunities for skills development we will develop a communication platform via an email list-serv to proactively communicate with providers who participate in the TiTAN program. A quarterly e-blast will be sent to all health care professionals involved in the TiTAN program. The e-blast will address the latest evidence-base practice, and skill development. Links to videos will also be provided. A webinar series will be scheduled to cover topics identified as interest by the primary health care providers. The webinar series will also be linked the Global Bridges EPACTT project.

Sponsors & Collaborators

  • Ottawa Heart Institute Research Corporation

    collaborator OTHER
  • Aristotle University Of Thessaloniki

    collaborator OTHER
  • Global Bridges Healthcare Alliance for Tobacco Dependence Treatment (Mayo Clinic)

    collaborator UNKNOWN
  • University of Ioannina

    collaborator OTHER
  • University of Nicosia

    collaborator OTHER
  • Pfizer Grants for Learning and Change

    collaborator UNKNOWN
  • University of Crete

    lead OTHER

Principal Investigators

  • Christos Lionis, MD, PhD · University of Crete

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-02-28
Primary Completion
2019-09-30
Completion
2019-12-31

Countries

  • Greece

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03040349 on ClinicalTrials.gov